DOI: 10.7860/JCDR/2024/70466.19688

Review Article

Psychiatry/Mental Health Section

Unlocking the Enigma of Cotard's Syndrome: A Narrative Review of its Clinical Manifestations and Therapeutic Strategies

MUDIT SAXENA[1], BHAGYESH SAPKALE[2], SUSHIL VARMA[3], SACHIN R GEDAM[4]

ABSTRACT

This narrative review explores Cotard's Syndrome (CS), a rare psychiatric condition characterised by delusions of death or non-existence, originally described by Jules Cotard in 1880. The syndrome presents a complex clinical picture, encompassing grandiosity, damnation, and physical breakdown. Despite its historical origins, CS remains poorly understood and often misdiagnosed. This review elucidates the clinical complexity, diagnostic challenges, and therapeutic strategies associated with CS. It highlights the neurological aspects, such as delusional misidentification and negation, shedding light on underlying mechanisms. Treatment approaches, including pharmacotherapy, Electroconvulsive Therapy (ECT), and psychotherapy, are discussed, emphasising the importance of ongoing mental health support across the illness's stages. The review draws from a comprehensive search methodology, encompassing diverse scholarly sources, to provide a nuanced understanding of CS. By increasing awareness among clinicians and researchers, this review aimed to improve diagnosis and treatment outcomes for individuals affected by this enigmatic syndrome.

Keywords: Brain neoplasms, Depressive disorder, Dissociative disorders, Electroconvulsive therapy, Mood disorders

INTRODUCTION

A common description of Cotard's Syndrome (CS) is the deluded conviction that one is dead or non existent. However, Jules Cotard's first account of the "delusion of negations" (1880) was far more detailed, with illusions of human disintegration and alteration, thoughts of damnation, and delusions and claims of immortality and grandeur [1]. On the other hand, it is thought to be a severe form of psychosis, hypochondria, or sadness. The illness is uncommon and yet not well understood. Cotard offered a classification system and multiple theories for the disease, emphasising how it differs from traditional persecutory delusions and speculating that it might be a form of grandiosity in reverse [2]. Many mental or neurological illnesses, including mood disorders, dissociative disorders, schizophrenia and other psychotic disorders, infections of the Central Nervous System (CNS), cerebrovascular disease, CNS neoplasms, and traumatic brain injury, may present with CS [3]. People in their middle or later years are usually affected by CS, and the typical picture also includes depression, which is present in approximately ninety percent of cases reported in the literature [4]. It has been suggested that having CS when younger increases the likelihood of developing bipolar disorder [5]. CS is commonly linked to cognitive inhibition and depression [6]. Usually, antidepressants, mood stabilisers, as well as Electroconvulsive Therapy (ECT) are used in the medical management of CS [7]. CS is a symptom of a number of neurological and mental disorders, although it is not a psychiatric diagnosis [8]. One possible cause of CS is valacyclovir toxicity [9]. This narrative review aims to provide a comprehensive understanding of CS, emphasising its clinical complexity, diagnostic challenges, and therapeutic strategies. By delving into the historical context, clinical manifestations, neurological aspects, contributing factors, and therapeutic approaches, this review sheds light on the intricacies of CS and its association with various mental and neurological disorders. Furthermore, it underscores the importance of ongoing mental health assistance and interdisciplinary collaboration in effectively managing CS across its different stages. This review, hopes to contribute to a deeper appreciation and awareness of CS among clinicians and researchers, ultimately facilitating improved diagnosis and treatment outcomes for individuals affected by this rare and enigmatic syndrome.

Search Methodolgy

The search methodology employed for this narrative review involved a comprehensive exploration of academic databases, including PubMed, Google Scholar, PsycINFO, and Scopus. Keywords related to CS and its various aspects, such as clinical manifestations, neurological aspects, contributing factors, and therapeutic approaches, were utilised to retrieve relevant literature. Boolean operators such as "AND" and "OR" were used in the search strategy, encompassing terms such as "CS," "Cotard's delusion," "walking corpse syndrome," "psychosis," "depression," "neurological aspects," "therapeutic strategies," "treatment," and "diagnostic challenges."

Additionally, the reference lists of identified articles and relevant review papers were scrutinised for additional sources to ensure a thorough review of the topic. The search was not restricted by publication date, but emphasis was placed on recent studies to encompass the latest developments in understanding and managing CS.

The CS is characterised by the false assumption that one is dead, nonexistent, decaying, or has lost vital organs or blood [10,11]. It is also referred to as walking corpse syndrome or Cotard's delusion. The signs and symptoms of CS appear in three phases [12]. The germination stage includes symptoms like hypochondria and psychotic sadness [1]. The syndrome peaks during the blooming period, resulting in illusions of denial [13]. The next stage is called chronic, and it is characterised by clinical sadness and severe delusions that do not go away [13].

Neurological aspect of Cotard's Syndrome (CS)

The CS patients disregard their physical and personal cleanliness and isolate themselves from others. The patient's warped perception of the outside world results from delusions of self-negation, which hinder their ability to make sense of their surroundings [6]. Perceptions of negation like this are typically associated with schizophrenia [3]. While powerful delusions of negation are similar to those observed in schizophrenia patients, hallucinations are not necessary for the identification of CS [14]. Delusional misidentification issues may be related to the underlying neurophysiology and psychopathology of CS [15]. Neurologically, denial of self and Capgras delusion are

connected [16]. CS delusions are believed to be caused by neural malfunctions in the amygdala, which link emotions to recognised faces, and the fusiform face area of the brain, which detects faces [17]. Due to neurological separation, the patient feels as though the face they are seeing does not belong to the person it should belong to [18]. As a result, it lacks the familiarity or recognition typically associated with it, leading to derealisation or a detachment from the surroundings. If the patient recognises the face they are observing, they may perceive it as the face of an imposter [19]. When a patient looks in the mirror, they may not associate their face with their own identity, leading them to believe that they are dead [20]. The psychological and neurological manifestations of CS are represented in [Table/Fig-1] [6,15-17,19,20].

Symptoms	Description
Delusions of negation of self	Warped perception of the outside world [6]
Isolation from others	Result of physical and personal cleanliness disregard [6]
Delusional misidentification	Underlying neurophysiology and psychopathology connection [15]
Capgras delusion	Connected to denial of self [16]
Neural malfunctions	Cause of CS delusions in amygdala and fusiform face area [17]
Derealisation	Detachment from surroundings following face observation [19]
Fraudulent face perception	Recognised face being observed [15,17]
Mirror face dissociation	Patient not associating their face with themselves [20]
Death belief	Result of mirror face dissociation [20]

[Table/Fig-1]: Characteristics of the symptoms of Cotard's Syndrome (CS) [6,15-17,19,20].

The CS is a rare psychiatric condition, making epidemiological data scarce. Due to its rarity and often misdiagnosed nature, the exact prevalence remains uncertain. However, it is believed to occur more frequently in individuals in their middle or later years of life [6]. CS is often associated with mood disorders, particularly depression [5]. Moreover, having CS at a younger age is associated with a higher likelihood of later acquiring bipolar disorder [6].

Clinical Manifestations and Contributing Factors of Cotard's Syndrome (CS)

Similar to schizophrenia, CS is typically found in patients who are psychotic. It is also present in brain tumours, derealisation, migraine headaches, and severe depression [21]. Lesions in the parietal lobe are linked to CS [22]. CS patients have a higher incidence of brain shrinkage, particularly in the median frontal lobe [23]. Adverse physiological reactions to drugs (such as acyclovir) and their prodrug precursors (such as valaciclovir) have also been linked to CS in patients [24]. The primary acyclovir metabolite, 9-Carboxymethoxymethylguanine (CMMG), can be found in high concentrations in the serum during CS [25]. If the dosage of acyclovir is reduced in CS patients with compromised renal function, they have a risk of experiencing delusional symptoms regularly [9]. Haemodialysis is helpful in curing delusions of CS [15]. CS patients may find it hard to comprehend that they have fewer organs, a malformed body, and that their condition is linked to a more severe form of depression [26]. The symptoms of CS and associated factors are mentioned in [Table/Fig-2] [15,21-26].

The prognosis of CS can vary depending on several factors, including the underlying cause, the severity of symptoms, and the individual's response to treatment [4]. In some cases, CS may be a symptom of an underlying neurological or psychiatric disorder such as schizophrenia, depression, or bipolar disorder [3]. If the underlying condition is effectively treated, the symptoms of CS may improve or resolve [2]. However, for individuals with primary CS, where it occurs without a clear underlying cause, the prognosis can be more complex [1,25]. Treatment typically involves a combination of psychotherapy and medication to address the underlying psychiatric symptoms [3].

Conditions/Factors	Description
Psychotic symptoms	Similar to schizophrenia [21]
Brain tumours	Can induce CS symptoms [21-23]
Derealisation	Detachment from surroundings [21]
Migraine headaches	May be linked to CS [24]
Severe depression	Often a co-occurring condition [21]
Parietal lobe lesions	Connected to CS development [22]
Brain shrinkage	Higher incidence in CS patients, particularly in the median frontal lobe [23]
Acyclovir and valaciclovir reaction	Adverse reactions linked to CS onset [24]
High CMMG levels in serum	Correlated with CS symptoms [25]
Haemodialysis for acyclovir overdose	Can quickly alleviate delusions in CS patients with renal issues [15]
Misconceptions about body and organs	Common symptom, difficulty accepting body image [26]

[Table/Fig-2]: Associated factors of Cotard's Syndrome (CS) [15,21-26].

The prognosis may be less favourable for individuals with severe or treatment-resistant cases of CS [23].

Therapeutic Approaches for Cotard's Syndrome (CS)

Antidepressants, antipsychotics, and mood stabilisers are examples of pharmaceutical treatments that have proven effective in treating CS [27]. Pharmacotherapy is less successful in treating depression in CS patients than ECT [28]. A successful course of treatment justifies discontinuing valaciclovir [9]. Haemodialysis has been linked to prompt clearance of CMMG and symptom relief [3]. Some examples of combination therapy using imipramine and risperidone have shown therapeutic effectiveness, although ECT is the most extensively documented treatment technique in the literature [29]. Left hemisphere lesions may co-exist with CS, and ECT may be the initial treatment for individuals with psychotic illness [30]. CS is typically treated with supportive care, medication, and psychotherapy. It is crucial to address underlying mental health issues such as depression during the germination stage. Doctors may prescribe antidepressants, such as Selective Serotonin Reuptake Inhibitors (SSRIs), during the germination stage of CS [5]. ECT and Cognitive-Behavioural Therapy (CBT) have been used to address erroneous thought processes and relieve symptoms during the blooming stage of CS, where delusions of denial are prominent [31]. Sustained mental health care is crucial during the chronic phase, often combining medication and psychotherapy [32]. The treatment of persistent depression and recurrent delusions associated with CS requires the support of family members, close companions, and healthcare professionals. Treatment approaches for CS are described in [Table/Fig-3] [3,5,27,29-32].

Treatment approach	Studies/approaches advocating
Pharmacotherapy	Antidepressants (e.g., SSRIs) may be prescribed during the germination stage [5]
	Few examples of imipramine and risperidone combination therapy have shown therapeutic effectiveness [29]
	Pharmacotherapy (e.g., antidepressants, antipsychotics, mood stabilisers) has proven effective, although less successful than ECT [27]
Electroconvulsive Therapy (ECT)	ECT is the most extensively documented treatment technique in the literature [29]
	ECT may be the initial treatment for individuals with psychotic illness and left hemisphere lesions [30]
Dialysis	Haemodialysis has been linked to prompt clearance of CMMG and symptom relief [3]
Psychotherapy	Cognitive-behavioural Therapy (CBT) has been used to address erroneous thought processes and relieve symptoms in the blooming stage [31]
Supportive care	Supportive care, including sustained mental health care, is crucial during the chronic phase [32]

Combination therapy	Combination therapy involving medication and psychotherapy is frequently used during the chronic phase [32]

[Table/Fig-3]: Treatment approaches for Cotard's Syndrome (CS) [3,5,27,29-32].

Documenting this review offers readers a comprehensive understanding of CS, aiding clinicians in accurate diagnosis and effective treatment. By synthesising information from diverse scholarly sources, it provides insights into the historical context, clinical manifestations, diagnostic challenges, and therapeutic strategies associated with CS. The review addresses the often misdiagnosed nature of CS, delineates differential diagnoses, and explores its neurological aspects, shedding light on underlying mechanisms. Furthermore, it discusses various treatment modalities, guiding clinicians in formulating tailored treatment plans. As there are already numerous publications on CS, this review adds value by presenting a contemporary synthesis of knowledge, contributing to the existing literature, and ultimately enhancing diagnosis and treatment outcomes for individuals affected by this rare syndrome.

CONCLUSION(S)

The CS goes beyond the well-known hallucination of death to provide a distinct and intricate clinical picture. Jules Cotard's comprehensive description of the condition in 1880 brought to light its complex combination of grandiosity, ideas of damnation, and physical breakdown. CS is rare and poorly understood, yet it is linked to several neurological and mental disorders. Its exclusion from most diagnostic manuals presents a diagnostic challenge. The neurological features, such as misidentification and delusions of negation, shed light on the underlying mechanisms of the disease. ECT, medication, and supportive care are used in combination for treatment, with a focus on the value of ongoing mental health assistance during the illness's many stages.

REFERENCES

[1] Dieguez S. Cotard syndrome. Front Neurol Neurosci. 2018;42:23-34.
[2] Mori T, Ikeda M, Tanabe H. Cotard syndrome. Ryoikibetsu Shokogun Shirizu. 2003;(38):124-27.
[3] Morgado P, Ribeiro R, Cerqueira JJ. Cotard syndrome without depressive symptoms in a schizophrenic patient. Case Rep Psychiatry. 2015;2015:643191.
[4] Moschopoulos NP, Kaprinis S, Nimatoudis J. Cotard's syndrome: Case report and a brief review of literature. Psychiatriki. 2016;27(4):296-302.
[5] Revilla J, Aliaga S, Lozano-Vargas A. Cotard and capgras syndrome in a patient with treatment-resistant schizophrenia. Case Rep Psychiatry. 2021;2021:6652336.
[6] Huarcaya-Victoria J, Ledesma-Gastañadui M, Huete-Cordova M. Cotard's syndrome in a patient with schizophrenia: Case report and review of the literature. Case Rep Psychiatry. 2016;2016:6968409.
[7] Nagy A, Vörös V, Tényi T. About the Cotard's syndrome. Neuropsychopharmacol Hung. 2008;10(4):213-24. PMID: 19213200.
[8] Grover S, Aneja J, Mahajan S, Varma S. Cotard's syndrome: Two case reports and a brief review of literature. J Neurosci Rural Pract. 2014;5(Suppl 1):S59-62.
[9] Kassam AS, Cunningham EA. Cotard syndrome resulting from valacyclovir toxicity. Prim Care Companion CNS Disord. 2018;20(1):17l02143.
[10] Funayama M, Takata T, Mimura M. Cotard's syndrome in anti-N-methyl-d-aspartate receptor encephalitis. Psychiatry Clin Neurosci. 2018;72(6):455-56.
[11] Oberndorfer R, Schönauer C, Eichbauer H, Klaushofer K, Friedrich F. Cotard syndrome in hypoactive delirium - A case report. Psychiatr Danub. 2017;29(4):500-02.
[12] Solimine S, Chan S, Morihara SK. Cotard Syndrome: 'I'm dead, so why do I need to eat?' Prim Care Companion CNS Disord. 2016;18(2). Doi: 10.4088/PCC.15l01862.
[13] Madani Y, Sabbe BGC. Cotard's syndrome. Different treatment strategies according to subclassification. Tijdschr Psychiatr. 2007;49(1):49-53.
[14] Dihingia S, Bhuyan D, Bora M, Das N. Cotard's delusion and its relation with different psychiatric diagnoses in a tertiary care hospital. Cureus. 2023;15(5):e39477.
[15] Helldén A, Odar-Cederlöf I, Larsson K, Fehrman-Ekholm I, Lindén T. Death delusion. BMJ. 2007;335(7633):1305.
[16] Ruminjo A, Mekinulov B. A case report of Cotard's syndrome. Psychiatry (Edgmont). 2008;5(6):28-29.
[17] Weiss C, Santander J, Torres R. Catatonia, neuroleptic malignant syndrome, and Cotard syndrome in a 22-year-old woman: A case report. Case Rep Psychiatry. 2013;2013:452646.
[18] Yesilkaya UH, Sen M, Karamustafalioglu N. New variants and new symptoms in COVID-19: First episode psychosis and Cotard's syndrome two months after infection with the B.1.1.7 variant of coronavirus. Schizophr Res. 2022;243:315-16.
[19] Huarcaya-Victoria J, Caqui M. Cotard's syndrome in a patient with major depressive disorder: Case report. Actas Esp Psiquiatr. 2017;45(5):248-55.
[20] Robertson C, Dunn T. "A ghost doesn't need insulin," Cotard's delusion leading to diabetic ketoacidosis and a body-mass index of 15: A case presentation. BMC Psychiatry. 2023;23(1):551.
[21] Ghaffari Nejad A, Mehdizadeh Zare Anari A, Pouya F. Effect of cultural themes on forming Cotard's syndrome: Reporting a case of Cotard's syndrome with depersonalization and out of body experience symptoms. Iran J Psychiatry Behav Sci. 2013;7(2):91-93.
[22] Taib NIA, Wahab S, Khoo CS, Tan HJ, Kamaruzaman L, Woon LSC, et al. Case report: Cotard's syndrome in anti-N-methyl D-aspartate (NMDA) receptor (anti-NMDAR) encephalitis. Front Psychiatry. 2022;13:779520.
[23] Mendez MF, Ramírez-Bermúdez J. Cotard syndrome in semantic dementia. Psychosomatics. 2011;52(6):571-74.
[24] Rajalakshmi R, Kumari R, Thappa DM. Acyclovir versus valacyclovir. Indian J Dermatol Venereol Leprol. 2010;76(4):439-44.
[25] Chou PH, Lin BT, Lan TH, Chan CH. Chronic Cotard's syndrome: Recovery from 2 years' bed-ridden status. Psychiatry Clin Neurosci. 2011;65(3):301.
[26] Vinkers DJ. Reaction to 'The syndrome of Cotard: An overview'. Tijdschr Psychiatr. 2008;50(6):391-92.
[27] Wani ZA, Khan AW, Baba AA, Khan HA, Wani QA, Taploo R. Cotard's syndrome and delayed diagnosis in Kashmir, India. Int J Ment Health Syst. 2008;2(1):01.
[28] Kjærgaard AL, Jensen LN, Taastrøm A, Rimvall MK. ECT for Cotard syndrome in a 13-year-old. Ugeskr Laeger. 2023;185(20):V11220696. PMID: 37264869. Available from: https://pubmed.ncbi.nlm.nih.gov/37264869.
[29] Machado L, de Lima Filho LE, Machado L. When the patient believes that the organs are destroyed: Manifestation of Cotard's syndrome. Case Rep Med. 2016;2016:5101357.
[30] Caliyurt O, Vardar E, Tuglu C. Cotard's syndrome with schizophreniform disorder can be successfully treated with electroconvulsive therapy: Case report. J Psychiatry Neurosci. 2004;29(2):138-41.
[31] Chan JH, Chen CH, Robson D, Tan HKL. Case report: Effective treatment of Cotard's syndrome: Quetiapine in combination with venlafaxine. Psychiatry Clin Neurosci. 2009;63(1):125-26.
[32] Montgomery JH, Vasu D. The use of electroconvulsive therapy in atypical psychotic presentations: A case review. Psychiatry (Edgmont). 2007;4(10):30-39.

PARTICULARS OF CONTRIBUTORS:
1. Undergraduate Student, Department of Medicine, Jawaharlal Nehru Medical College, Datta Meghe Institute of Higher Education and Research, Wardha, Maharashtra, India.
2. Undergraduate Student, Department of Medicine, Jawaharlal Nehru Medical College, Datta Meghe Institute of Higher Education and Research, Wardha, Maharashtra, India.
3. Professor, Department of Pharmacology, Jawaharlal Nehru Medical College, Datta Meghe Institute of Higher Education and Research, Wardha, Maharashtra, India.
4. Assistant Professor, Department of Psychiatry, Jawaharlal Nehru Medical College, Datta Meghe Institute of Higher Education and Research, Wardha, Maharashtra, India.

NAME, ADDRESS, E-MAIL ID OF THE CORRESPONDING AUTHOR:
Mudit Saxena,
Undergraduate Student, Department of Medicine, Jawaharlal Nehru Medical College,
Datta Meghe Institute of Higher Education and Research,
Wardha-442005, Maharashtra, India.
E-mail: mudit81203@gmail.com

PLAGIARISM CHECKING METHODS: [Jain H et al.]
- Plagiarism X-checker: Mar 03, 2024
- Manual Googling: Apr 13, 2024
- iThenticate Software: May 04, 2024 (4%)

ETYMOLOGY: Author Origin

EMENDATIONS: 6

AUTHOR DECLARATION:
- Financial or Other Competing Interests: None
- Was informed consent obtained from the subjects involved in the study? NA
- For any images presented appropriate consent has been obtained from the subjects. NA

Date of Submission: **Mar 02, 2024**
Date of Peer Review: **Apr 11, 2024**
Date of Acceptance: **May 06, 2024**
Date of Publishing: **Jul 01, 2024**